Sildenafil sublingual - Benuvia Therapeutics
Alternative Names: Sildenafil sublingual spray - INSYS TherapeuticsLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator INSYS Therapeutics, Inc
- Developer Benuvia Therapeutics
- Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Erectile dysfunction
Most Recent Events
- 23 Mar 2021 Sildenafil sublingual is available for licensing as of 23 Mar 2021. https://www.benuvia.com/
- 23 Mar 2021 Benuvia Therapeutics has patents protection for sildenafil sublingual spray formulation, before March 2021 (Benuvia Therapeutics pipeline, March 2021)
- 01 Mar 2021 Phase-II clinical trials in Erectile dysfunction in USA (Sublingual) before March 2021 (Benuvia Therapeutics pipeline, March 2021)